{"title":"4例smarca4缺陷肿瘤患者氟脱氧葡萄糖（FDG） PET/CT成像分析及临床治疗评价","authors":"Xueqin Zhao, Wei Fu","doi":"10.1007/s00432-025-06207-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to characterize SMARCA4-deficient tumors using <sup>18</sup>F-FDG PET/CT and explore its role in diagnosis, staging, therapeutic response assessment, and prognosis across multiple pathological subtypes.</p><p><strong>Methods: </strong>We retrospectively analyzed four patients with histologically confirmed SMARCA4-deficient tumors. Clinical features, <sup>18</sup>F-FDG PET/CT findings, pathological subtypes, molecular characteristics, treatment modalities, and outcomes were evaluated.</p><p><strong>Results: </strong>All tumors demonstrated high FDG uptake, indicating elevated metabolic activity. Imaging patterns varied by subtype, including undifferentiated carcinoma and non-small cell lung cancer. Treatment strategies involved chemotherapy, immunotherapy, and targeted therapy with diverse responses. SMARCA4 deficiency was associated with poor prognosis and potential treatment resistance.</p><p><strong>Conclusion: </strong><sup>18</sup>F-FDG PET/CT is valuable in the comprehensive assessment of SMARCA4-deficient tumors. Combined with molecular profiling, it enhances diagnostic accuracy and aids in individualized treatment planning. This case series offers preliminary guidance for clinicians managing this rare, aggressive tumor type.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"182"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12133917/pdf/","citationCount":"0","resultStr":"{\"title\":\"Fluorodeoxyglucose (FDG) PET/CT imaging analysis and clinical treatment evaluation in patients with SMARCA4-deficient tumors: case reports of four patients.\",\"authors\":\"Xueqin Zhao, Wei Fu\",\"doi\":\"10.1007/s00432-025-06207-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study aims to characterize SMARCA4-deficient tumors using <sup>18</sup>F-FDG PET/CT and explore its role in diagnosis, staging, therapeutic response assessment, and prognosis across multiple pathological subtypes.</p><p><strong>Methods: </strong>We retrospectively analyzed four patients with histologically confirmed SMARCA4-deficient tumors. Clinical features, <sup>18</sup>F-FDG PET/CT findings, pathological subtypes, molecular characteristics, treatment modalities, and outcomes were evaluated.</p><p><strong>Results: </strong>All tumors demonstrated high FDG uptake, indicating elevated metabolic activity. Imaging patterns varied by subtype, including undifferentiated carcinoma and non-small cell lung cancer. Treatment strategies involved chemotherapy, immunotherapy, and targeted therapy with diverse responses. SMARCA4 deficiency was associated with poor prognosis and potential treatment resistance.</p><p><strong>Conclusion: </strong><sup>18</sup>F-FDG PET/CT is valuable in the comprehensive assessment of SMARCA4-deficient tumors. Combined with molecular profiling, it enhances diagnostic accuracy and aids in individualized treatment planning. This case series offers preliminary guidance for clinicians managing this rare, aggressive tumor type.</p>\",\"PeriodicalId\":15118,\"journal\":{\"name\":\"Journal of Cancer Research and Clinical Oncology\",\"volume\":\"151 6\",\"pages\":\"182\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12133917/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cancer Research and Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00432-025-06207-9\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00432-025-06207-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Fluorodeoxyglucose (FDG) PET/CT imaging analysis and clinical treatment evaluation in patients with SMARCA4-deficient tumors: case reports of four patients.
Purpose: This study aims to characterize SMARCA4-deficient tumors using 18F-FDG PET/CT and explore its role in diagnosis, staging, therapeutic response assessment, and prognosis across multiple pathological subtypes.
Methods: We retrospectively analyzed four patients with histologically confirmed SMARCA4-deficient tumors. Clinical features, 18F-FDG PET/CT findings, pathological subtypes, molecular characteristics, treatment modalities, and outcomes were evaluated.
Results: All tumors demonstrated high FDG uptake, indicating elevated metabolic activity. Imaging patterns varied by subtype, including undifferentiated carcinoma and non-small cell lung cancer. Treatment strategies involved chemotherapy, immunotherapy, and targeted therapy with diverse responses. SMARCA4 deficiency was associated with poor prognosis and potential treatment resistance.
Conclusion: 18F-FDG PET/CT is valuable in the comprehensive assessment of SMARCA4-deficient tumors. Combined with molecular profiling, it enhances diagnostic accuracy and aids in individualized treatment planning. This case series offers preliminary guidance for clinicians managing this rare, aggressive tumor type.
期刊介绍：
The "Journal of Cancer Research and Clinical Oncology" publishes significant and up-to-date articles within the fields of experimental and clinical oncology. The journal, which is chiefly devoted to Original papers, also includes Reviews as well as Editorials and Guest editorials on current, controversial topics. The section Letters to the editors provides a forum for a rapid exchange of comments and information concerning previously published papers and topics of current interest. Meeting reports provide current information on the latest results presented at important congresses.
The following fields are covered: carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; and epidemiology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
